2d:I[856015,["/_next/static/immutable/chunks/1xzisbplk9czp.js","/_next/static/immutable/chunks/3j2i1faptc_-9.js","/_next/static/immutable/chunks/0fma7nlq6immz.js","/_next/static/immutable/chunks/08tq8rmv423j5.js","/_next/static/immutable/chunks/1chr5wkk3j58k.js","/_next/static/immutable/chunks/37kmmh_zm4dov.js","/_next/static/immutable/chunks/311zvdjfxff-f.js","/_next/static/immutable/chunks/1a_hqhrsle_n_.js"],"default"] 2e:T6578,

Summary Table

Domain	Detail
Risk Factors	Recent infection 1 to 4 weeks prior (most commonly Campylobacter jejuni gastroenteritis), post-viral illness (CMV, EBV, Zika, influenza), recent surgery, vaccination (rare association)
Etiology	Post-infectious autoimmune-mediated destruction of peripheral nerve myelin (or axons in axonal variants) through molecular mimicry
Patient Presentation	Progressive, symmetric, ascending weakness beginning in the lower extremities, with or without paresthesias; may report difficulty walking, climbing stairs, or rising from a chair; progresses over days to weeks
Classic Physical Exam	Symmetric flaccid paralysis with areflexia or hyporeflexia, distal-to-proximal weakness pattern, possible bilateral facial nerve palsy (cranial nerve VII), respiratory muscle weakness, intact sensation or mild sensory loss; bowel and bladder function typically preserved
Key Diagnostic Results	CSF: albuminocytologic dissociation (elevated protein with normal cell count). Nerve conduction studies (NCS)/EMG: demyelinating pattern with prolonged distal latencies, conduction block, and temporal dispersion. Pulmonary function: declining forced vital capacity (FVC)
Management	IV immunoglobulin (IVIG) or plasmapheresis (equally effective, do not combine). Serial FVC monitoring. Intubation if FVC < 20 mL/kg or negative inspiratory force (NIF) < -20 to -30 cmH₂O. Corticosteroids are not effective and should not be used.
Keywords	"Ascending paralysis," "areflexia," "post-diarrheal illness," "albuminocytologic dissociation," "recent Campylobacter infection," "progressive symmetric weakness," "difficulty breathing after viral illness"

1. Pathophysiology

Guillain-Barré Syndrome (GBS) is the most common cause of acute flaccid paralysis in previously healthy individuals. The disease is driven by molecular mimicry: surface antigens on an infecting organism (most classically Campylobacter jejuni) share structural similarity with ganglioside components on peripheral nerve myelin or axonal membranes. The immune system, having mounted a response against the pathogen, cross-reacts with peripheral nerve tissue.

In the most common subtype, acute inflammatory demyelinating polyneuropathy (AIDP), the autoimmune attack targets the myelin sheath of peripheral nerves. Macrophages and complement-mediated injury strip away myelin, leading to saltatory conduction failure. This explains why nerve conduction studies show prolonged distal latencies and conduction block: the nerve impulse cannot jump efficiently between nodes of Ranvier. When enough myelin is destroyed, the nerve effectively stops conducting signals, producing flaccid paralysis and loss of deep tendon reflexes.

The reason weakness ascends from distal to proximal is anatomical: the longest peripheral nerves are affected first because they have more surface area vulnerable to immune attack, and the blood-nerve barrier is weakest at nerve roots and terminal segments. The pattern therefore begins in the feet and legs, climbs to the thighs and trunk, and may eventually involve the diaphragm and intercostal muscles. This is why respiratory failure is the most feared complication and the leading cause of death if not anticipated.

Cranial nerves, particularly facial nerve (CN VII), can also be involved because they are peripheral nerves. Bilateral facial weakness is a classic finding that distinguishes GBS from central nervous system pathology. Autonomic nerve fibers may also be affected, producing dysautonomia (labile blood pressure, cardiac arrhythmias, urinary retention), which is an underrecognized cause of mortality in these patients.

Importantly, GBS is a lower motor neuron disease. This is why the exam findings include flaccid (not spastic) paralysis, absent (not hyperactive) reflexes, and no upper motor neuron signs such as Babinski sign or clonus.

2. Classification and Clinical Manifestation

Subtype	Target	Key Features	Geographic Predominance
Acute Inflammatory Demyelinating Polyneuropathy (AIDP)	Myelin sheath	Classic ascending weakness, areflexia, sensory symptoms may be present; most common form overall	North America, Europe
Acute Motor Axonal Neuropathy (AMAN)	Motor axons (gangliosides GM1, GD1a)	Pure motor involvement, no sensory loss, more rapid onset, strongly associated with C. jejuni and anti-GM1 antibodies	Asia, Central/South America
Acute Motor and Sensory Axonal Neuropathy (AMSAN)	Motor and sensory axons	Similar to AMAN but with sensory involvement; tends to be more severe with slower recovery	Less common overall
Miller Fisher Syndrome (MFS)	Cranial nerves, peripheral nerves (anti-GQ1b antibodies)	Classic triad: ophthalmoplegia, ataxia, areflexia; descending variant; anti-GQ1b antibody is highly characteristic	Japan (higher prevalence), worldwide
Acute Pandysautonomia	Autonomic nerve fibers	Severe autonomic dysfunction: orthostatic hypotension, anhidrosis, gastroparesis, urinary retention; motor strength may be relatively preserved	Rare
Pharyngeal-Cervical-Brachial Variant	Cranial and upper extremity nerves	Weakness of oropharyngeal, neck, and shoulder muscles; may mimic botulism or brainstem stroke	Rare

The most important distinction for exam purposes is between AIDP (demyelinating, the prototype) and Miller Fisher Syndrome (the triad of ophthalmoplegia, ataxia, and areflexia with anti-GQ1b antibodies). A vignette describing eye movement abnormalities with ataxia and absent reflexes after a recent infection should point directly to Miller Fisher.

3. Diagnostic Workup

Test	Role	Expected Findings	Timing
Lumbar puncture (CSF analysis)	Best initial test to support diagnosis	Albuminocytologic dissociation: elevated protein (often > 0.45 g/L) with normal WBC count (< 10 cells/μL)	May be normal in the first 48 to 72 hours; peaks at 2 to 4 weeks
Nerve conduction studies / EMG	Most accurate (confirmatory) test	Demyelinating pattern: prolonged distal motor latencies, reduced conduction velocities, conduction block, prolonged or absent F-waves, temporal dispersion	Abnormalities may not appear until 1 to 2 weeks after symptom onset
Forced vital capacity (FVC) and NIF	Critical for monitoring respiratory status	FVC < 20 mL/kg, NIF weaker than -20 to -30 cmH₂O, or declining trend indicates need for intubation	Serial measurement every 4 to 6 hours in acute phase
Anti-ganglioside antibodies	Supportive, subtype identification	Anti-GM1 in AMAN; anti-GQ1b in Miller Fisher Syndrome	Order when clinical picture suggests a variant
MRI of spine with contrast	Adjunctive	Enhancement of nerve roots (especially cauda equina), helps exclude compressive myelopathy	When diagnosis uncertain or need to rule out structural lesion

The clinical diagnosis of GBS is primarily made at the bedside. When a patient presents with rapidly progressive, symmetric ascending weakness with areflexia following a recent infection, GBS should be at the top of the differential.

Lumbar puncture is the best initial test ordered to support the clinical suspicion. The hallmark finding is albuminocytologic dissociation, meaning the CSF protein is elevated while the white blood cell count remains normal. This pattern occurs because inflammation at the nerve roots disrupts the blood-nerve barrier, allowing protein to leak into the CSF, but there is no infectious or inflammatory cellular infiltrate in the subarachnoid space. A critical exam point: if the CSF shows elevated WBC (pleocytosis) along with elevated protein, you must consider alternative diagnoses such as HIV-associated polyradiculopathy, Lyme disease, CMV radiculitis, or leptomeningeal carcinomatosis. Another important caveat is that the CSF may be entirely normal within the first 48 to 72 hours of symptom onset, so a normal LP very early in the course does not exclude GBS.

Nerve conduction studies and electromyography (NCS/EMG) are the most accurate confirmatory test. In AIDP, the classic findings are prolonged distal motor latencies, slowed conduction velocities, conduction block, and prolonged or absent F-waves. These findings reflect the underlying segmental demyelination. In axonal variants (AMAN, AMSAN), conduction velocities may be preserved but amplitudes are reduced, indicating axonal loss rather than myelin damage. Like the LP, NCS/EMG may be normal very early in the disease course, and repeat testing at 1 to 2 weeks may be needed.

Respiratory monitoring deserves its own emphasis because it is the most testable management decision. Serial measurements of FVC and NIF (negative inspiratory force) are not diagnostic for GBS per se, but they determine the single most important clinical action: when to intubate. The "20/30/40 rule" is a useful framework:

FVC < 20 mL/kg
NIF weaker than -30 cmH₂O (that is, the patient cannot generate adequate negative pressure)
More than 40% decline in FVC from baseline

Any of these thresholds warrants elective intubation. Do not wait for arterial blood gas abnormalities or clinical signs of respiratory distress, as these are late findings in neuromuscular respiratory failure. Pulse oximetry is also unreliable in this setting because oxygen saturation may remain normal until the patient is on the verge of respiratory arrest.

4. Management and Treatment

Phase	Intervention	Details
Acute immunotherapy (choose one)	IV Immunoglobulin (IVIG)	0.4 g/kg/day IV for 5 days (total 2 g/kg); preferred in most settings due to easier administration
Acute immunotherapy (choose one)	Plasmapheresis (TPE)	5 exchanges over 7 to 14 days; equally effective as IVIG; preferred if IVIG contraindicated
Respiratory support	Serial FVC/NIF monitoring	Every 4 to 6 hours; intubate if FVC < 20 mL/kg, NIF < -20 to -30 cmH₂O, or rapid decline
Supportive care	DVT prophylaxis	Subcutaneous heparin or LMWH for immobilized patients
	Pain management	Gabapentin or carbamazepine for neuropathic pain (common and undertreated)
	Autonomic monitoring	Telemetry for arrhythmia, BP monitoring for labile hypertension/hypotension
	Physical/occupational therapy	Begin early; rehabilitation is the primary driver of functional recovery
Not recommended	Corticosteroids	No benefit; do not use alone or in combination with IVIG

The acute management of GBS centers on two parallel priorities: immunomodulatory therapy and airway protection.

IVIG at a dose of 0.4 g/kg/day for 5 consecutive days is the most commonly chosen first-line therapy. It works by neutralizing pathogenic antibodies, modulating complement activation, and downregulating the autoimmune response. It is generally preferred over plasmapheresis because it is easier to administer, does not require central venous access, and has fewer hemodynamic complications. Side effects include headache, aseptic meningitis, renal toxicity (particularly with sucrose-containing formulations), and thromboembolic events.

Plasmapheresis (therapeutic plasma exchange, TPE) is equally effective and involves physically removing circulating autoantibodies from the patient's blood. It is typically delivered as 5 exchanges over 7 to 14 days. It is preferred when IVIG is contraindicated, such as in patients with IgA deficiency (who may develop anaphylaxis to IVIG) or severe renal insufficiency.

A critically testable point: do not combine IVIG and plasmapheresis. Clinical trials have shown that combining them provides no additional benefit over either alone, and plasmapheresis would simply wash out the administered immunoglobulin.

Corticosteroids have no role in the treatment of GBS. Despite their efficacy in many other autoimmune conditions, multiple randomized controlled trials have demonstrated that corticosteroids do not improve outcomes in GBS and may even delay recovery. This is one of the most frequently tested "traps" on licensing exams.

The second priority is respiratory management. The most important clinical decision in GBS is determining when to intubate. Because GBS causes neuromuscular respiratory failure (the lungs themselves are normal, but the muscles of breathing are weak), standard indicators like oxygen saturation and arterial blood gas are insensitive until very late. Instead, bedside pulmonary function testing with FVC and NIF should be performed every 4 to 6 hours. Elective intubation is safer and preferred over emergent intubation in a patient who is acutely decompensating.

Additional supportive measures include:

DVT prophylaxis with subcutaneous heparin, as immobilized patients are at high risk for venous thromboembolism
Neuropathic pain control with gabapentin or pregabalin, since pain is reported in up to 70% of GBS patients and is frequently undertreated
Autonomic monitoring with continuous telemetry, because dysautonomia (tachycardia, bradycardia, blood pressure swings) is a significant contributor to mortality
Early rehabilitation with physical and occupational therapy once the patient is clinically stable, as this is the primary determinant of long-term functional recovery

Most patients with GBS recover, though recovery may take weeks to months. Approximately 80% of patients regain the ability to walk independently within 6 months, though residual fatigue and minor weakness are common. About 5 to 10% of patients experience incomplete recovery with significant disability, and 3 to 5% die, most often from respiratory failure, pulmonary embolism, or cardiac arrest from dysautonomia.

5. Differential Diagnosis and Distractors

Differential	Why It Is Similar	Key Discriminator
Transverse myelitis	Acute onset weakness, possible post-infectious trigger	Has a sensory level on exam, upper motor neuron signs (hyperreflexia, Babinski) below the lesion, and early bladder dysfunction; MRI shows spinal cord lesion
Myasthenia gravis	Weakness, possible cranial nerve involvement	Weakness is fatigable (worsens with repetitive use, improves with rest), predominantly affects ocular and bulbar muscles, reflexes are preserved; positive AChR antibodies and edrophonium test
Botulism	Acute flaccid paralysis, areflexia, respiratory failure	Weakness is descending (begins with cranial nerves: diplopia, dysphagia, then descends), prominent autonomic findings (mydriasis, dry mouth), associated with food exposure or wound; EMG shows incremental response
Tick paralysis	Ascending flaccid paralysis with areflexia; clinically nearly identical	Careful skin exam reveals an embedded tick; removal of tick leads to rapid improvement; CSF is normal
Spinal cord compression	Acute weakness with possible progression	Upper motor neuron signs (spasticity, hyperreflexia, Babinski), sensory level, bowel/bladder dysfunction early; MRI shows compressive lesion
Poliomyelitis	Acute flaccid paralysis, post-febrile illness	Asymmetric weakness, predominantly motor, CSF shows pleocytosis (not albuminocytologic dissociation), occurs in unvaccinated populations
Chronic inflammatory demyelinating polyneuropathy (CIDP)	Demyelinating polyneuropathy with areflexia and elevated CSF protein	Time course is chronic (> 8 weeks of progressive or relapsing symptoms); GBS is acute (nadir within 4 weeks); CIDP responds to corticosteroids (GBS does not)
Hypokalemia / hypokalemic periodic paralysis	Acute symmetric weakness, possible areflexia	Check serum potassium; weakness resolves with potassium replacement; no antecedent infection; no CSF abnormalities
HIV-associated polyradiculopathy	Progressive weakness, elevated CSF protein	CSF shows pleocytosis (not the classic normal cell count of GBS); patient has known HIV risk factors; often caused by CMV in advanced immunosuppression

6. Traps and High-Yield Pearls

The single most common way students lose points on GBS questions is by selecting corticosteroids as treatment. Because GBS is autoimmune and because corticosteroids work in nearly every other autoimmune neurological condition (multiple sclerosis, myasthenia gravis, CIDP), it is natural to assume they would work here. They do not. This is a deliberately placed distractor, and the correct answers are always IVIG or plasmapheresis.

The second major trap involves respiratory monitoring. A vignette may describe a patient with GBS who "appears comfortable" and has normal oxygen saturation, then ask for the next best step. Students who select "continue observation" or "obtain an ABG" will miss the point. The correct answer is serial FVC measurement, because neuromuscular respiratory failure is a ventilatory problem (inadequate air movement), not an oxygenation problem. By the time the oxygen saturation drops or the ABG shows CO₂ retention, the patient is in extremis.

A third testing angle involves early normal CSF. A question may present a patient with classic GBS symptoms but a normal lumbar puncture. Students must recognize that the CSF protein elevation may take several days to develop, and a normal LP within the first 48 to 72 hours does not exclude the diagnosis. The next step in this scenario is to proceed with nerve conduction studies or to repeat the LP later.

For Miller Fisher Syndrome, the tested competency is recognizing the triad (ophthalmoplegia, ataxia, areflexia) and linking it to anti-GQ1b antibodies. This variant can appear as a standalone question or as a distractor designed to mimic brainstem stroke or Wernicke encephalopathy. The absence of altered mental status and the presence of areflexia should steer you toward Miller Fisher.

Finally, remember the distinction between GBS and CIDP. Both are demyelinating polyradiculoneuropathies with similar CSF and NCS findings. The discriminator is time course: GBS reaches its nadir within 4 weeks and then plateaus or improves. If symptoms continue to progress beyond 8 weeks, the diagnosis shifts to CIDP, which does respond to corticosteroids. This distinction is a favorite testing point for differentiating acute from chronic autoimmune neuropathy.

The core competency being tested across all GBS questions is the ability to recognize a post-infectious ascending paralysis, order the correct diagnostic tests in the correct sequence, initiate appropriate immunotherapy while avoiding corticosteroids, and anticipate respiratory failure before it becomes clinically apparent.

1e:["$","$L2d",null,{"article":{"id":"76f81ee7-963a-4746-b0b9-53c2028eb4fe","title":"Guillain-Barre Syndrome (GSB)","content":"$2e","category":"Neurologi","created_at":"2026-07-30T08:11:07.984664+00:00","status":"published","subcategory":null},"questionCount":1,"sections":[{"id":"section-pathophysiology","num":"01","title":"Pathophysiology"},{"id":"section-classification-and-clinical-manifestation","num":"02","title":"Classification and Clinical Manifestation"},{"id":"section-diagnostic-workup","num":"03","title":"Diagnostic Workup"},{"id":"section-management-and-treatment","num":"04","title":"Management and Treatment"},{"id":"section-differential-diagnosis-and-distractors","num":"05","title":"Differential Diagnosis and Distractors"},{"id":"section-traps-and-high-yield-pearls","num":"06","title":"Traps and High-Yield Pearls"}],"hasSummaryTable":true}]